CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The company focuses on developing Probody therapeutics which addresses clinically-validated cancer targets in immuno-oncology that are difficult to drug and lead to concerns about damage to healthy tissues or toxicities.
| Website: | www.cytomx.com |
| Email: | ckeenan@cytomx.com |
| Main Phone: | +1 650 515-3185 |
| Address: | 151 Oyster Point Boulevard |
| Address 2: | Suite 400 |
| State: | CA |
| City / Town: | South San Francisco |
| Country: | USA |
| Postal Code: | 94080 |
| Exchange: | NGS |
| CEO: | Sean A. McCarthy |
| Employees: | 139 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Gathering Data... Please wait CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The company focuses on developing Probody therapeutics which addresses clinically-validated cancer targets in immuno-oncology that are difficult to drug and lead to concerns about damage to healthy tissues or toxicities.
| Website: | www.cytomx.com |
| Email: | ckeenan@cytomx.com |
| Main Phone: | +1 650 515-3185 |
| Address: | 151 Oyster Point Boulevard |
| Address 2: | Suite 400 |
| State: | CA |
| City / Town: | South San Francisco |
| Country: | USA |
| Postal Code: | 94080 |
| Exchange: | NGS |
| CEO: | Sean A. McCarthy |
| Employees: | 139 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
| Last Price 10.64 | Change $ -0.25 | Change % -2.30 | Tick N/A |
| Bid 10.00 | Bid Size 300.00 | Ask 10.75 | Ask Size 200.00 |
| Open 10.74 | High 10.79 | Low 10.44 | Prev Close 10.89 |
| Last Trade | Volume 289,121 | 52 Wk Hi 27.20 | 52 Wk Low 8.94 |
| Market Cap 482.1 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 45,311,464.00 | EPS (TTM) -1.93 | PE Ratio N/A | Exchange NGS |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 11 | 84 |
| Number of Buys | 6 | 34 |
| Number of Sells | 5 | 50 |
| Net Activity | -3511 | -1977686 |
| Last 10 Buys | Shares |
|---|---|
| Flynn E James | 1,000 |
| Flynn E James | 1,000 |
| Cynthia Ladd | 1,000 |
| W. Michael Kavanaugh | 1,000 |
| Frederick W. Gluck | 1,000 |
| Frederick W. Gluck | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Debanjan Ray | 1,000 |
| Debanjan Ray | 1,000 |
| Sean A. McCarthy | 1,000 |
| Debanjan Ray | 1,000 |
| Frederick W. Gluck | 1,000 |
| Debanjan Ray | 1,000 |
| Debanjan Ray | 1,000 |
| Rachel Humphrey | 1,000 |
| Frederick W. Gluck | 1,000 |
| Debanjan Ray | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 40 | 40 | 40 | 40 |
| Low Target Price Estimate | 37 | 37 | 37 | 37 |
| Mean Target Price Estimate | 39 | 39.2 | 39.2 | 39 |
| Standard Deviation | 1.26 | 1.3 | 1.3 | 1.26 |
| Date of Most Recent Estimate | 06/05/18 | 05/22/18 | 05/22/18 | 06/05/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-15 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-15 |
| 3 | Initial statement of beneficial ownership of securities | 1 | 2018-06-15 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-15 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-15 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-15 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-15 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 8-K | Report of unscheduled material events or corporate changes. | 4 | 2018-06-04 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 7 | 6 | 6 | 6 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.25 | 1.29 | 1.29 | 1.29 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
